Industry veteran Carlos Orantes is the new Chief Executive Officer (CEO) of Meridien Research — a private, seven-clinic site network with 125 employees that focuses on a wide range of medical and mental health research studies.
Carlos will spearhead Meridien’s strategy of organic and inorganic growth alongside the Company’s C-suite executives, Stacey Colado (COO), Dr. Andrew Cutler (CMO) and Duane Miskelly (CFO). With a management team of talented industry executives, 11 experienced Principal Investigators, a robust pipeline of studies and the support of its investors, Meridien is well-positioned to continue to build upon its recent success.
“With his extensive clinical trial knowledge and track record of successful business development, Carlos is the right person to guide the excellent team we have here at Meridien,” said interim Meridien Research CEO and Director, Thomas Vandervort, “Carlos’ leadership, values and experience make him ideal to lead Meridien and push us to achieve our full potential.”
Carlos has more than 25 years of experience in the life sciences, contract research, and drug development arena. He was most recently the CEO of Clinical Research Investments, which included Accel Clinical Research, Populace Health, Vitalis Research and Clinical Trial Connections as subsidiaries. Carlos’s prior experience includes leadership roles at Frontage Laboratories, AVANZA Laboratories, Bridge Laboratories, Gene Logic and Covance Laboratories.
“Meridien Research has a legacy of significant accomplishments,” Carlos explained. “Together, our plan is to continue delivering high quality and responsible research with a passion so that we are the company of choice for our stakeholders including patients, team and customers.”
Carlos continued, “My goals in leading Meridien Research as the CEO are to continue advancing the wheels of progress in clinical research and to build on the strength of our company for our patients, physicians, people and partners. We will accomplish this together through organic growth including new therapeutic areas and through acquisitions of existing businesses that can be accretive to our company imperatives.”
Carlos earned his Bachelor of Science degree in Biology at George Washington University and his Master of Business Administration degree from Old Dominion University. He is also a Six Sigma Black Belt.
If you would like to learn more about Meridien Research or any of the new corporate team, please visit the Staff area of our website below.